Properties for optimal PDT sensitizers.

[1]  J. Levy,et al.  Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. , 1983, Journal of immunology.

[2]  J Moan,et al.  A comparison of different photosensitizing dyes with respect to uptake C3H-tumors and tissues of mice. , 1987, Cancer letters.

[3]  M C Berenbaum,et al.  meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. , 1986, British Journal of Cancer.

[4]  B. Wilson,et al.  IN VIVO and POST MORTEM MEASUREMENTS OF THE ATTENUATION SPECTRA OF LIGHT IN MAMMALIAN TISSUES , 1985, Photochemistry and photobiology.

[5]  J Moan,et al.  Effect of bleaching of porphyrin sensitizers during photodynamic therapy. , 1986, Cancer letters.

[6]  Q. Peng,et al.  PHOTOSENSITIZING EFFICIENCIES, TUMOR‐ and CELLULAR UPTAKE OF DIFFERENT PHOTOSENSITIZING DRUGS RELEVANT FOR PHOTODYNAMIC THERAPY OF CANCER , 1987, Photochemistry and photobiology.

[7]  G. Jori,et al.  Role of high-, low- and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. , 1986, Cancer letters.

[8]  H Lenz,et al.  Measurements on the depth of penetration of light (0.35–1.0 µm) in tissue , 1977, Radiation and environmental biophysics.

[9]  A. Girotti,et al.  GLUCOSE ADMINISTRATION AUGMENTS IN VIVO UPTAKE AND PHOTOTOXICITY OF THE TUMOR‐LOCALIZING FRACTION OF HEMATOPORPHYRIN DERIVATIVE , 1989, Photochemistry and photobiology.

[10]  J. Moan,et al.  Photodynamic effects on human cells exposed to light in the presence of hematoporphyrin. pH effects. , 1980, Cancer letters.